Erasca keeps the market's attention, shares on Nasdaq

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 20:42.

Erasca Inc. (US29479V1044) trades on Nasdaq as a targeted oncology developer with a U.S.-listed share price and an active investor-relations page. The companys latest disclosed capital-market reference point is its investor site, while Nasdaq remains the main international anchor for the stock.

Nasdaq listing and IR page

Erasca presents itself as a precision oncology company focused on RAS/MAPK pathway biology and drug development. Its investor-relations site and corporate website are the primary company sources for pipeline, governance and financing material. Erasca investor relations

The Nasdaq venue matters for discovery and liquidity because it places the shares alongside other U.S. biotech names that trade on the same exchange. That makes the listing comparable with peers such as Arrowhead and Revolution Medicines in the broader oncology and platform-therapy segment.

What the calendar shows

For a development-stage biotech, the key weekday lens is the company calendar: earnings dates, conference appearances and clinical updates. A dated market-data reference on Nasdaq helps frame where the shares trade, even when the next hard catalyst is a scheduled company communication. Financial Times market data hub

Analyst coverage in U.S. biotech often clusters around pipeline milestones and cash position rather than near-term revenue. In that context, the next scheduled update matters more than short-term trading noise for Erasca shares.

Pipeline as the product

Erasca's core business is not a consumer product but a drug-development pipeline in precision oncology. That means investors track lead molecules, study milestones and capital allocation rather than unit sales.

Where the stock trades today

Erasca shares were last verifiable on Nasdaq in U.S. dollars; the exact live quote was not available in the provided sources at publication time.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.